Samsung Biologics highlights CDO capabilities at PEGS Boston

Company expands client engagement through presentations, business meetings
Offers end-to-end CDO solutions from early development to IND filing

[Kim Saemi, Edaily Reporter] Samsung Biologics said on May 13, it is participating in the Protein Engineering & Cell Therapy Summit (PEGS) Boston, a leading global conference on biopharmaceutical technologies.

Samsung Biologics said it is participating in the Protein Engineering & Cell Therapy Summit (PEGS) Boston, a leading global conference on biopharmaceutical technologies. [Source=Samsung Biologics]

PEGS Boston is the world’s largest conference dedicated to protein and antibody therapeutics, bringing together more than 2,400 participants to discuss the latest in biologics innovation. Held annually each May in Boston, this year’s event runs May 12~16.

At the summit, Samsung Biologics set up a dedicated meeting room for business discussions with global pharmaceutical companies, focusing on strengthening engagement with key clients. The company promoted its contract development organization, or CDO, capabilities particularly in high-concentration formulation development and candidate developability assessments.

On May 12, the first day of the event, the company hosted a luncheon presentation titled “Streamlining Drug Development: From Developability Assessment to High-Concentration Formulation Development.” Heon-Chang Lim, head of the formulation development group at the CDO Development Center, introduced key CDO service platforms, including S-HiCon and DEVELOPICK.

S-HiCon, launched in October 2024, supports the development of ultra-high concentration formulations by leveraging the company’s formulation expertise. Compared to conventional low-concentration biologics, high-concentration formulations can reduce patient injection burden and lower costs for storage and transport.

DEVELOPICK, first released in October 2022 and now in its third version, is a developability assessment platform that helps identify optimal drug candidates by evaluating protein properties using only small sample amounts during the discovery stage.

Samsung Biologics has built a suite of nine proprietary CDO technology platforms to meet diverse client needs. In addition to S-HiCon and DEVELOPICK, the portfolio includes:

S-CHOice, a proprietary cell line platform

S-DUAL, a bispecific antibody platform

S-CHOsient, a transient expression platform

S-Glyn, an analytics-based material support platform

S-Tensify, for high-concentration formulation development

S-AfuCHO, an afucosylated cell line platform

S-Opticharge, for regulating protein charge variants

Together, the platforms allow Samsung Biologics to provide customized CDO services from early-stage development through investigational new drug (IND) filing.

The company continues to expand its global footprint by participating in international conferences. After attending the J.P. Morgan Healthcare Conference in January and DCAT Week in March, Samsung Biologics plans to join the BIO International Convention also known as BIO USA next month in Boston, the world’s largest biotech and pharmaceutical trade show.

김새미 (bird@edaily.co.kr)